Literature DB >> 31346036

Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor.

Vivek Tripathi1, Ekjot Kaur1, Suhas Sampat Kharat1, Mansoor Hussain1, Arun Prasath Damodaran1, Swati Kulshrestha1, Sagar Sengupta2.   

Abstract

The gene encoding the tumor suppressor p53 is mutated in most cancers. p53 expression is known to be tightly controlled by several E3 ligases. Here, we show that F-box and WD repeat domain-containing 7α (FBW7α), the substrate-recognition component of the SCFFBW7 multiprotein E3 ligase complex, targets both WT and tumor-derived mutants of p53 for proteasomal degradation in multiple human cancer cell lines (HCT116 and U2OS). We found that lack of FBW7α stabilizes p53 levels, thereby increasing its half-life. p53 ubiquitylation and subsequent degradation require the F-box and the C-terminal WD40 repeats in FBW7α. The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3β (GSK3β) and DNA-dependent protein kinase (DNA-PK), respectively. These phosphorylation events created a phosphodegron that enhanced p53 binding to FBW7α, allowing for the attachment of polyubiquitin moieties at Lys-132 in p53. FBW7α-dependent p53 polyubiquitylation apparently occurred during and immediately after DNA double-strand breaks induced by either doxorubicin or ionizing radiation. Accordingly, in cells lacking FBW7α, p53 induction was enhanced after DNA damage. Phosphodegron-mediated polyubiquitylation of p53 on Lys-132 had functional consequences, with cells in which FBW7α-mediated p53 degradation was abrogated exhibiting enhancement of their tumorigenic potential. We conclude that p53, which previously has been reported to transactivate FBW7, is also targeted by the same E3 ligase for degradation, suggesting the presence of a regulatory feedback loop that controls p53 levels and functions during DNA damage.
© 2019 Tripathi et al.

Entities:  

Keywords:  DNA damage; E3 ubiquitin ligase; Fbw7; SCFFbw7 complex; p53; tumor suppressor gene; ubiquitin ligase; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2019        PMID: 31346036      PMCID: PMC6737220          DOI: 10.1074/jbc.AC119.008483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Targeted inactivation of p53 in human cells does not result in aneuploidy.

Authors:  Fred Bunz; Christine Fauth; Michael R Speicher; Annie Dutriaux; John M Sedivy; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

3.  MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.

Authors:  Akihiro Ito; Yoshiharu Kawaguchi; Chun-Hsiang Lai; Jeffrey J Kovacs; Yuichiro Higashimoto; Ettore Appella; Tso-Pang Yao
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

4.  Hot-spot mutants of p53 core domain evince characteristic local structural changes.

Authors:  K B Wong; B S DeDecker; S M Freund; M R Proctor; M Bycroft; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination.

Authors:  Sagar Sengupta; Steven P Linke; Remy Pedeux; Qin Yang; Julie Farnsworth; Susan H Garfield; Kristoffer Valerie; Jerry W Shay; Nathan A Ellis; Bohdan Wasylyk; Curtis C Harris
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

6.  P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.

Authors:  Gad Asher; Joseph Lotem; Peter Tsvetkov; Veronica Reiss; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

7.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

8.  hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53.

Authors:  Takashi Kimura; Mitsukazu Gotoh; Yusuke Nakamura; Hirofumi Arakawa
Journal:  Cancer Sci       Date:  2003-05       Impact factor: 6.716

9.  hCDC4 gene mutations in endometrial cancer.

Authors:  Charles H Spruck; Heimo Strohmaier; Olle Sangfelt; Hannes M Müller; Michael Hubalek; Elisabeth Müller-Holzner; Christian Marth; Martin Widschwendter; Steven I Reed
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

10.  Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity.

Authors:  G A Turenne; B D Price
Journal:  BMC Cell Biol       Date:  2001-07-16       Impact factor: 4.241

View more
  8 in total

Review 1.  Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities.

Authors:  Lilian Makgoo; Salerwe Mosebi; Zukile Mbita
Journal:  Front Mol Biosci       Date:  2022-05-10

2.  Comparing cell-free circulating tumor DNA mutational profiles of disease-free and nonresponders patients with oropharyngeal squamous cell carcinoma.

Authors:  Alok R Khandelwal; Adam H Greer; Mickie Hamiter; Janmaris Marin Fermin; Thomas McMullen; Tara Moore-Medlin; Glenn Mills; Jose M Flores; Hong Yin; Cherie-Ann O Nathan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-09-01

3.  p53 and FBXW7: Sometimes Two Guardians Are Worse than One.

Authors:  María Galindo-Moreno; Servando Giráldez; M Cristina Limón-Mortés; Alejandro Belmonte-Fernández; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  Cancers (Basel)       Date:  2020-04-16       Impact factor: 6.639

4.  Loss of TRIM31 promotes breast cancer progression through regulating K48- and K63-linked ubiquitination of p53.

Authors:  Yafei Guo; Qin Li; Gang Zhao; Jie Zhang; Hang Yuan; Tianyu Feng; Deqiong Ou; Rui Gu; Siqi Li; Kai Li; Ping Lin
Journal:  Cell Death Dis       Date:  2021-10-14       Impact factor: 8.469

Review 5.  Clinical significance of FBXW7 loss of function in human cancers.

Authors:  Jingyi Fan; Marcia Bellon; Mingyi Ju; Lin Zhao; Minjie Wei; Liwu Fu; Christophe Nicot
Journal:  Mol Cancer       Date:  2022-03-26       Impact factor: 27.401

6.  FBXW7 inactivation induces cellular senescence via accumulation of p53.

Authors:  Longyuan Gong; Danrui Cui; Dian Liu; Xiao Shen; Hui Pan; Xiufang Xiong; Yongchao Zhao
Journal:  Cell Death Dis       Date:  2022-09-14       Impact factor: 9.685

Review 7.  The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression.

Authors:  Tingting Zou; Zhenghong Lin
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 8.  Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.

Authors:  Scott Bang; Sandeep Kaur; Manabu Kurokawa
Journal:  Int J Mol Sci       Date:  2019-12-30       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.